Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Current Deferred Revenue (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Current Deferred Revenue for 6 consecutive years, with $449000.0 as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 85.11% to $449000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $449000.0 through Dec 2025, down 85.11% year-over-year, with the annual reading at $449000.0 for FY2025, 85.11% down from the prior year.
  • Current Deferred Revenue hit $449000.0 in Q4 2025 for Bolt Biotherapeutics, down from $1.9 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $5.2 million in Q3 2021 to a low of $449000.0 in Q4 2025.
  • Historically, Current Deferred Revenue has averaged $2.5 million across 5 years, with a median of $2.4 million in 2023.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 129.56% in 2022 and later plummeted 85.11% in 2025.
  • Year by year, Current Deferred Revenue stood at $2.9 million in 2021, then crashed by 30.53% to $2.0 million in 2022, then increased by 10.44% to $2.2 million in 2023, then surged by 36.98% to $3.0 million in 2024, then plummeted by 85.11% to $449000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for BOLT at $449000.0 in Q4 2025, $1.9 million in Q3 2025, and $2.5 million in Q2 2025.